EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Moolec Science's Enterprise Value is €67.6 Mil.
Moolec Science's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €3.8 Mil. Therefore, Moolec Science's EV-to-FCF for today is 17.69.
The historical rank and industry rank for Moolec Science's EV-to-FCF or its related term are showing as below:
FRA:K8P'
s EV-to-FCF Range Over the Past 10 Years
Min: -23.68 Med: -1.73 Max: 47.98
Current: 17.63
During the past 5 years, the highest EV-to-FCF of Moolec Science was 47.98. The lowest was -23.68. And the median was -1.73.
FRA:K8P's EV-to-FCF is ranked worse than 52.89% of 329
companies
in the Biotechnology industry
Industry Median: 16.38
vs FRA:K8P: 17.63
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Moolec Science's PE Ratio (TTM) for today is calculated as:
Moolec Science's share price for today is €5.55.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Moolec Science's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €-71.391.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Moolec Science EV-to-FCF Related Terms
Moolec Science EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Moolec Science's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Moolec Science's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Moolec Science EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Moolec Science's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Moolec Science's EV-to-FCF falls into.
Moolec Science's current Enterprise Value is €67.6 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Moolec Science's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €3.8 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Moolec Science (FRA:K8P) has a EV-to-FCF of 17.69 as of Jul. 07, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Moolec Science and its competitors. According to the industry distribution chart, Moolec Science ranks #174 out of 329 companies in the Biotechnology industry, placing it in the top 52.9%.
Is Moolec Science's EV-to-FCF too high?
Moolec Science's current EV-to-FCF is 17.69. The Biotechnology industry median EV-to-FCF is 16.38. Moolec Science's value of 17.69 is 8% above this industry median. Based on the distribution chart, Moolec Science ranks #174 out of 329 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Moolec Science has a GF Score™ of 46/100, reflecting its overall financial health beyond just this single metric.
How does Moolec Science's EV-to-FCF compare to GNPX and ADIL?
According to the Biotechnology industry distribution chart, Moolec Science ranks #174 out of 329 companies for EV-to-FCF. This places Moolec Science in the lower half of its industry. The industry median EV-to-FCF is 16.38. Moolec Science's value of 17.69 is 8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 16.38, based on 329 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Moolec Science's current EV-to-FCF of 17.69 is 8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Moolec Science and its competitors. For the Biotechnology industry, the median EV-to-FCF is 16.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Moolec Science's current EV-to-FCF is 17.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Moolec Science stock overvalued right now?
Moolec Science (FRA:K8P) has a current EV-to-FCF of 17.69. The stock's GF Value™ is €61.07, compared to a current price of €5.55 — trading 90.9% below its estimated fair value. The current EV-to-FCF is 17.69 and 8% above the Biotechnology industry median of 16.38. Moolec Science's overall GF Score™ is 46/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Moolec Science (FRA:K8P), the current EV-to-FCF is 17.69 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Moolec Science (FRA:K8P) Overvalued in 2026?
Based on GuruFocus' analysis, Moolec Science stock appears to be undervalued.
The current stock price of €5.55 is trading 90.9% below its estimated GF Value™ of €61.07.
Key valuation signals for FRA:K8P:
EV-to-FCF: 17.69
GF Value™: €61.07 vs. price of €5.55 (90.9% below fair value)
Industry Position: 8% above the Biotechnology median (#174 of 329)
No single metric tells the full story. See the FRA:K8P stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Moolec Science SA is a science-based ingredient company focused on producing real animal proteins in plants through Molecular Farming, a technology in the alternative protein landscape. Its purpose is to upgrade the taste, nutrition, and affordability of alternative protein products while building a more sustainable and equitable food system. The company has various products in its pipeline, such as; TSP Valorasoy which is a soy protein product to produce vegetable proteins with texture and fibrousness similar to those of meat, Glaso, a safflower oil with high levels of gamma-linolenic acid, SPC2 which is a plant-based chymosin, YEEA1, an extract derived from a novel yeast biomass with specific properties, and others. The company's maximum revenues from operations in Argentina.
46GF Score
Get the complete analysis for FRA:K8P
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:K8P has been successfully added to your 
